LLY10-Kfiled 2026-02-12

Eli Lilly and's 10-K: fiscal year ended 2025-12-31

Annual report, fiscal year ended 2025-12-31.

Read the filing on sec.gov ↗All documents and exhibits ↗Accession 0000059478-26-000013

What changed

Each line against the same period a year earlier. The math is under each line; the filing is one click away.

Latest fiscal year vs the year before

10-K filed 2026-02-12 ↗

Year ended	2024-12-31	2025-12-31	Change
Revenue(65,179 − 45,043) ÷ \|45,043\| × 100 = +44.7% ($ millions)	$45.0B	$65.2B	+44.7%
Net income(20,640 − 10,590) ÷ \|10,590\| × 100 = +94.9% ($ millions)	$10.6B	$20.6B	+94.9%
Diluted earnings per share(22.95 − 11.71) ÷ \|11.71\| × 100 = +96.0% ($ a share)	$11.71	$22.95	+96.0%
Diluted share count (weighted)(899 − 904) ÷ \|904\| × 100 = −0.5% (millions of shares)	904.1M	899.3M	−0.5%
Operating cash flow(16,813 − 8,818) ÷ \|8,818\| × 100 = +90.7% ($ millions)	$8.8B	$16.8B	+90.7%

Both columns as reported in the latest filing, so a restated prior period shows its restated figure. n/m: not meaningful (the prior figure is zero or of the other sign). Concepts: us-gaap:Revenues, us-gaap:NetIncomeLoss, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding, us-gaap:NetCashProvidedByUsedInOperatingActivities.

LLY’s other recent filings

Filed	Form	What it is
2026-10-29	10-Q	Quarterly report, period ended 2026-09-30
2026-10-29	8-K	Current report: Results of operations
2026-08-05	10-Q	Quarterly report, period ended 2026-06-30
2026-08-05	8-K	Current report: Results of operations
2026-05-20	8-K	Current report: Other events sec.gov ↗
2026-05-07	8-K	Current report: Shareholder vote results sec.gov ↗
2026-04-30	10-Q	Quarterly report, period ended 2026-03-31
2026-04-30	8-K	Current report: Results of operations

Not financial advice. For education only.